A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer
GANNET53 (Ganetespib in metastatic, p53 mutant, platinum-resistant ovarian cancer) is a FP7 research project funded by the European Commission. The project started in October 2013 and aims at improving prognosis and quality of life in platinum-resistant, p53 mutant ovarian cancer patients. The project is planned for 5.5 years with a funding of 6 million Euros.
Who are we?
GANNET53 is a group of passionate collaborators, click here to find out more about them.
What we do?
Learn more about our clinical trials and translational research...
© 2013 all rights reserved